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Clinical T3 (cT3) prostate cancer is present in 12-40% of all patients who are
newly diagnosed with prostate cancer.
1-3 Although the gold standard for treating
these patients remains controversial, the optimal management of locally advanced
prostate cancer should be individually tailored based on the clinical stage, the
biopsy Gleason sum (GS) and the prostate specific antigen (PSA) level, as well as
the patient’s age, co-morbidities, and personal preference. Until recently, definite
radical prostatectomy (RP) has not been considered as the standard treatment for
cT3 high risk prostate cancer which has grown beyond the periprostatic tissue or
seminal vesicles without lymph node invasion or distant metastases.
1 Because RP
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Purpose: Down-staging of clinical T3 (cT3) prostate cancer after radical prosta-
tectomy (RP) is not uncommon due to the inaccuracy of the currently available
staging modalities, although selected down-staged cT3 patients can be a candidate
for definitive RP. We identified the significant predictors for down-staging of cT3
after RP. Materials and Methods: We included 67 patients with cT3 stage prostate
cancer treated with radical perineal prostatectomy (RPP) between 1998 and 2006
and reviewed their medical records retrospectively. The clinical stage was obtained
according to the DRE, the prostate biopsy findings, and the prostate MRI. Results:
Fifty three (79%) patients with cT3 prostate cancer were down-staged to pT2 after
RP. The percent of positive cores had the strongest association with down-staging
of cT3 [p = 0.01, odds ratio (OR) = 6.3], followed by baseline prostate specific
antigen (PSA) (p = 0.03, OR = 5.0), the biopsy Gleason sum (GS) (p = 0.03, OR =
4.7), and the maximum tumor volume of the positive cores (p = 0.05, OR = 4.0).
When the cut-off points of significant parameters which were a PSA < 10 ng/mL,
a percent of positive cores ≤ 30%, a maximum tumor volume of the positive cores
≤ 75% and GS ≤ 7 were combined, the sensitivity, specificity, and positive
predictive value were 0.25%, 1.00%, and 100%, respectively. Conclusion: The
percent of positive cores ≤ 30%, serum PSA < 10 ng/mL, the biopsy GS ≤ 7, and
the maximum tumor volume of the positive cores ≤ 75% were the significant
predictors of down-staging cT3 disease after RP.
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INTRODUCTIONcured only a minority of patients when applied as a mono-
therapy, the combination of hormonal treatment (HT) with
radiotherapy (RT) was previously considered state of the
art for the management of cT3 disease. 
However, down-staging (pT2) or up-staging (pT4 or
pN+) after RP is not a rare clinical error due to the inade-
quate diagnostic accuracy of the preoperative staging
evaluation, and in one study, the proportion of clinical
over-staging was reported to be 27% of all the hormone-
naive cT3 patients.
2 Several authors reported very good
long-term outcomes after surgery as the initial treatment
for locally-advanced prostate cancer, especially in the case
of over-staged patients with cT3 prostate cancers.
2,3 The
favorable cancer-specific survival rate and the overall
survival rate after RP at the 10-yr follow-up for patients
with cT3 disease were reported to be > 75% and 60%, res-
pectively, in previous studies.
4 Similarly, Freedland, et al.
reported that among 56 patients who had clinical stage T3a
disease treated by RP alone by a single surgeon between
1987 and 2003, PSA-free survival at 15 years after surgery
was 49% and metastasis-free survival and cause-specific
survival at 15 years after surgery were 73% and 84%, res-
pectively.
5 But the evaluation of the Surveillance, Epide-
miology, and End Results database reveals that only 9% of
men with locally advanced, nonmetastatic disease are
treated surgically (± HT), and even for men with a long
life-expectancy.
5 Although Partin tables which use a com-
bination of preoperative PSA, biopsy GS, and clinical
stages are the most widely used tool to predict final pathol-
ogical staging after RP for organ-confined tumors, rare
useful preoperative predictive parameters for locally ad-
vanced disease are available.
6 In addition, retrospective
data show that the patients who are young and have organ
confined diseases demonstrate the best postoperative
results in terms of curative and erectile function.
7 If over-
staged cT3 prostate cancer could be reliably identified be-
fore determining the treatment plan by clinical parameters,
these predictors could be used as selection criteria of
patients that can benefit from RP and can be a candidate
for nerve-preservation. In this study, we found the useful
predictors for down-staging of cT3 after RP and evaluated
the determined predictors’ diagnostic efficacy at specific
cut-off points.
Sixty-seven patients with cT3 prostate cancer that were
treated with radical perineal prostatectomy (RPP) at our
institution between 1998 and 2006 were included in this
study. We reviewed the patients’ medical records, retro-
spectively, and excluded patients with a history of neo-
adjuvant HT or RT. The routine preoperative clinical stag-
ing work-up included taking the history and a physical
examination that included a digital rectal examination
(DRE), determining the serum baseline PSA level, the trans-
rectal ultrasound (TRUS) guided prostate biopsy, MRI, and
bone scan. 
The serum PSA level was determined on an ambulatory
basis prior to biopsy with the Hybritech, Tosoh, or Abbot
assay. All the prostate biopsies were performed using a
standard 18 gauge biopsy gun and the number of biopsy
sites ranged from six to ten with additional targeted biopsies
when a hypoechoic or suspicious lesion existed. For each
needle biopsy, certain variables were assessed, including
the GS, the percent of tumor as a function of all the biopsy
tissue, the number of cancer positive cores and the total
number of cores from all the biopsy sites. 
MRI was performed using a whole-body 3-T MR scanner
with pelvic phasedarray coil and were performed accord-
ing to the same protocol. All MRI studies were performed
more than 3-4 weeks after prostate biopsy to reduce the
possibility of post-biopsy artifacts. All data were evaluated
by two experienced radiologists with knowledge of clinical
data PSA, biopsy GS, and DRE findings. We considered
the MRI findings in determining clinical stage and cT3
disease was defined as a state with suspicious extra-capsular
extension (ECE) or seminal vesicle invasion (SVI) in the
MRI. The following criteria were used for the diagnosis of
ECE: tumor tissue in the extraprostatic tissue, obliteration
of the rectoprostatic angle, bulging of the prostate contour
caused by tumor, asymmetry or direct involvement of the
neurovascular bundles, thickening, retraction or irregularity
of the prostate capsule, disruption of the prostatic capsule
adjacent to the tumor, and stranding of the periprostatic
fatty tissue.
8,9 The criterion for seminal vesicle invasion
was abnormal asymmetric low signal intensity within the
lumen on T2-weighted images. All the prostates from RP
were examined while they were still fresh by a pathologist.
Routine sections of all the surgical margins, including the
prostatic base, apex and peripheral zone, the capsule and
periprostatic soft tissue, seminal vesicle, urethra, and blad-
der neck were examined on permanent staining. Based on
these findings, ECE, SVI, and/or positive surgical margins
(PSM) were recorded. Diseases extending into but not
through the prostatic capsule were considered negative for
ECE.
Univariate analysis of the clinical characteristics between
the down-staged cT3 group and the non down-staged
group after RP was assessed by Student t-test, Mann-
Whitney U-test, and chi-square test. A logistic regression
multivariate analysis was performed to evaluate the ability
of the preoperative PSA level, the PSA density (PSAD:
PSA divided by prostate volume measured with TRUS),
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MATERIALS AND METHODSand the prostate biopsy findings, including the biopsy GS,
the percent of positive cores, and the maximum tumor
volume of the positive cores to predict down-staging after
RP. The receiver operating characteristics (ROC) curve
analysis derived area under the curve (AUC) estimates
determined the cut-off points of each predictor, and their
sensitivity, specificity, and positive predictive value (PPV)
were then analyzed. The SPSS version 17.0
® (SPSS Inc,
Chicago, IL, USA) for Windows was used for statistical
analysis and a probability (p) level of less than 0.05 was
considered statistically significant. 
Of the total 67 patients with cT3 stage disease, 79% (n = 53)
were down-staged after RPP and neurovascular bundle
saving technique was applied to 10 (15%) patients (unila-
teral: 2, bilateral: 8). Among the 53 down-staged patients,
21 (39.6%) and 32 (60.4%) patients were cT3a (positive
ECE) and cT3b (positive seminal vesicle invasion), respec-
tively. Table 1 summarizes the comparative analysis of
clinical and pathological features between the down-staged
group and non down-staged group after RPP. In the 53
down-staged patients, 10 (18.9%) patients had a positive
surgical margin in their post-prostatectomy specimen com-
pared to 11 (78.6%) patients in the non down-staged group
(p < 0.001). The nerve-sparing rate was significantly dif-
ferent between the down-staged group (9.4%) and non
down-staged group (35.7%) (p = 0.014). When the PSA
cut-off value of 0.4 ng/mL was used as the definition of
biochemical recurrence, oncologic outcomes including pos-
toperative biochemical recurrence rate (17.0% vs. 78.6%, p
< 0.001), biochemical recurrence free interval (52 months
vs. 8.5 months, p < 0.001), and 3-year biochemical recur-
rence free probability (89% vs. 36%, p < 0.001) showed
meaningfully better results in the down-staged group com-
pared to the non down-staged group.
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RESULTS
Table 1. Univariate Analysis of the Clinical and Prostate Needle Biopsy Findings as a Function of the Down-
Staging after Radical Prostatectomy
Down-staged cT3 Non down-staged cT3
pvalue
(≤pT2c) (≥pT3a)
Number of patients 53 (79%) 14 (21%)
Follow up duration (mean  ± SD) (month) 51 ± 24.2 26 ± 8.2 < 0.001
Age (mean  ± SD) (yr) 63 ± 4.8  66 ± 4.8 0.103
Median initial PSA (range) (ng/mL) 8.51 (2.74 - 207.00) 18.88 (3.50 - 67.48) 0.008
PSAD (mean  ± SD) (ng/mL
2) 0.4 ± 0.37 0.90 ± 0.79 < 0.001
Percent of positive cores (mean  ± SD) (%) 38 ± 19.4 52 ± 22.4 0.020
Maximum tumor volume of 
52 ± 30.6 61  ± 33.9 0.028
the positive cores (mean  ± SD) (%)
Biopsy Gleason sum (mean  ± SD) 7 ± 1.0 8 ± 1.3 0.006
Clinical stage 0.16
cT3a 21 (39.6%) 4 (28.6%)
cT3b 32 (60.4%) 10 (71.4%)
Pathologic stage
pT3a 0 3 (21.4%)
pT3b 0 11 (78.6%)
N+ 0 0
Positive surgical margin 10 (18.9%) 11 (78.6%) < 0.001
Neurovascular bundle saved 5 (9.4%) 5 (35.7%) 0.014
Post-op Gleason sum (mean  ± SD) 7 ± 0.9 8 ± 1.1 0.006
Biochemical recurrence rate
17.0% (9) 78.6% (11) < 0.001
(PSA ≥0.4 ng/mL)
Median Biochemical recurrence free
52 (4 - 138) 8.5 (1 - 81) < 0.001
interval (months) (range)
3-year biochemical recurrence free probability
89% 36% < 0.001
(PSA< 0.4 ng/mL)
PSA, prostate specific antigen; PSAD, prostate specific antigen density.The baseline PSA level (p < 0.001), PSAD (p < 0.001),
the biopsy GS (p = 0.01), the percent of positive cores (p =
0.02), and the maximum tumor volume of the positive cores
(p = 0.03) showed significant differences on univariate
analysis between the down-staged cT3 prostate cancer
group and the other group. But after multivariate logistic
regression analysis, the percent of positive cores had the
strongest association with down-staging of cT3 disease [p
= 0.01, odds ratio (OR) = 6.3, 1.86 ≤ 95% CI ≤ 8.0], and
this was followed by the preoperative PSA level (p = 0.03,
OR = 5.0, 1.5 ≤ 95% CI ≤ 481.8), the biopsy GS (p = 0.03,
OR = 4.7, 1.3 ≤ 95% CI ≤ 196.7), and the maximum tumor
volume of the positive cores (p = 0.05, OR = 4.0, 1.0 ≤
95% CI ≤8.9) (Table 2). 
The ROC curve analysis demonstrated the largest AUC
for the preoperative PSA (0.832), and this was followed by
the biopsy GS (0.706), the percent of positive cores (0.687),
and the maximum tumor volume of the positive cores
(0.592) (Fig. 1). Table 3 lists the sensitivity, specificity, and
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Table 2. Multivariate Analysis of the Clinical and Biopsy Findings for Predicting the Down-Staging of Clinical 
T3 Prostate Cancer
OR (95% CI) pvalue 
Initial PSA (≤10 vs. > 10) (ng/mL) 5.0 (1.5 - 481.8) 0.026
PSAD (ng/mL
2) 0.5 (0.13 - 2.55) 0.482
Percent of positive cores (%) 6.3 (0.86 - 8.0) 0.012
Maximum tumor volume of the positive cores (%) 4.0 (1.0 - 8.9) 0.046
Biopsy Gleason sum (≤7 vs. > 7) 4.7 (1.3 - 196.7) 0.030
PSA, prostate specific antigen; PSAD, prostate specific antigen density.
Table 3. The Sensitivity, Specificity, PPV, and NPV at Each Cut-Off Value of the Preoperative Predictors for 
Predicting Down-Staging of Clinical T3 Prostate Cancer 
Cut-off value Sensitivity Specificity PPV (%) NPV (%)
Preoperative PSA (ng/mL)
10 0.698 0.857 94.87 42.86
20 0.925 0.286 81.67 42.86
Percent of positive cores (%)
30 0.358 1.000 100.00 29.17
50 0.717 0.571 86.36 34.78
75 0.943 0.143 84.65 40.00
Maximum tumor volume of the positive cores (%)
25 0.264 0.786 82.35 28.21
50 0.415 0.714 83.33 24.32
75 0.660 0.500 83.33 28.00
Biopsy Gleason sum
6 0.019 1.000 87.5 25.58
7 0.396 0.786 88.23 50.00
Combination of a PSA level <10 ng/mL and a percent of positive core ≤30% and a maximum tumor 
volume of the positive core ≤75% and a biopsy Gleason sum ≤7
0.245 1.000 100.00 25.93
PPV, positive predictive value; NPV, negative predictive value; PSA, prostate specific antigen.
Fig. 1. The ROC curve analysis of each clinical parameter for predicting down-
staging of clinical T3 prostate cancer area under curve (AUC). Preoperative
PSA, 0.832; Biopsy Gleason sum (GS), 0.706; Percent of positive cores, 0.687;
Maximum tumor volume of the positive cores, 0.592. ROC, receiver operating
characteristics; PSA, prostate specific antigen.PPV at the cut-off value of each predictor for down-staging
cT3 disease. Among the 28 (42%) patients with an initial
PSA level ≤ 10 ng/mL, only 57% were down-staged accor-
ding to the radical prostatectomy specimen. But if the pre-
op PSA level was less than 10 ng/mL, then 95% of the
patients would have had a pathological stage ≤ pT2. If the
cut off value of the percent of positive cores was deter-
mined as 30%, then the sensitivity, specificity, and PPV
were 0.36, 1.00, and 100% in contrast to 0.94, 0.14, and
85%, respectively, when the percent of positive cores was
determined as 75%. In addition, the sensitivity, specificity,
and PPV were 0.66, 0.50, and 83%, respectively, at a 75%
maximum tumor volume of the positive core and these
values were 0.40, 0.79 and 88%, respectively, at a biopsy
GS of 7. Finally, when the cut-off points of significant
parameters which were a PSA < 10 ng/mL, a percent of
positive cores ≤ 30%, a maximum tumor volume of the
positive cores ≤ 75% and GS ≤ 7 were combined, then the
sensitivity, specificity, and PPV were determined to be 0.25,
1.00, and 100%, respectively.
The treatment goal for locally-advanced prostate cancer is
to potentially cure the disease, prolong the biochemical
progression-free or metastasis-free survival, and improve
the quality of life. Although RP has been generally recom-
mended for patients with a PSA < 20 ng/mL, a disease
stage ≤ cT3a and a biopsy GS ≤ 8, RP could be an alterna-
tive choice which has acceptable surgery-related morbidity
for selected patients with cT3 disease if the improved sur-
gical techniques such as radical extirpation and extended
lymph node dissection were performed and, especially if
these patients were down-staged to pT2 after RP. Although
definitive surgery is not very popular in treating cT3 disease,
recent studies have presented very convincing long-term
outcomes after surgery as primary treatment, with 5- and
10-year overall survival of 75-97.6% and 60-94.8%, and 5-
and 10-year cancer specific survival of 85-100% and 57-
90%, respectively.
2,3,10,11
In several factors influencing the outcome in cT3 pros-
tate cancer, the pathologic stage eventually has an impor-
tant influence in postoperative cancer control.
12,13 The
results of our study supported this by showing better oncol-
ogic surgical outcomes in the down-staged group after RP
compared to the non down-staged group. Despite various
efforts to enhance the accuracy of the prediction of non-
organ confined diseases, the down-staging rate of cT3
diseases is known to be about 17-30% and these patients
could be candidates for RP according to the generally
accepted standards.
13,14 Predictive algorithms based on multi-
variate regression analysis and neural networks are su-
perior to standard empirical methods of clinical staging
and they have been validated in several studies.
12 Although
currently, DRE, biopsy GS, and serum PSA alone or in
combination do not accurately predict disease extent for
the individual patient, a combination of all three has been
recommended as a basis of predictive algorithms for pros-
tate cancer staging. Partin tables, a pretreatment table using
the combination of preoperative serum PSA, biopsy GS,
and clinical stage are the most widely used tools to predict
the final histopathology in clinically organ-confined disease
(stage cT1c-cT2c) and have been demonstrated to be more
accurate than any single clinical staging method alone.
7
Since the introduction of these nomograms at Johns Hop-
kins Hospital, the presence of pathologically non-organ-
confined cancers has dropped from about two-thirds in the
prenomogram era to less than half, and the incidence of
either seminal vesicle involvement or pelvic lymph node
metastasis decreased from 20% to 10%. 
However, predictive nomograms which can provide a
basis for decision-making and patient counseling before
treating clinically locally-advanced prostate cancer is still
lacking. Our study used the combination of baseline PSA
level and biopsy findings including GS, the percent of
positive cores, and finally the maximum tumor volume of
the positive cores to predict down-staging after RP in this
study. In one recent study, patients were divided into three
PSA subgroups (≤ 10 ng/mL, > 10-20 ng/mL, and > 20
ng/mL) and two GS subgroups [≤ 7 (3 + 4) and ≤ 7 (4 + 3)]
and the table stratifies patients into six demarcated risk
groups.
15 While in the first group, consisting of patients
with PSA ≤ 10 ng/mL and GS ≤ 7 (3 + 4), under-staging
was only 6% (5% pT3b and 1% pT4), in the sixth group
consisting of patients with PSA > 20 ng/mL and GS ≤ 7 (4
+ 3), under-staging was as high as 68% (44% pT3b and
22% pT4). They reported accurate predictive ability of the
table for SVI (AUC 0.73, 0.653 ≤ 95% CI ≤ 0.803) and for
adjacent structure involvement (AUC 0.80, 0.732 ≤ 95%
CI ≤ 0.860) in ROC analysis. Veltri and co-workers com-
bined serum PSA levels, patients’ age, the number of posi-
tive biopsy cores, the percentage of tumor involvement in
a core, GS, the presence of a Gleason grade of 4 or 5, and
the tumor location by sextant biopsy to predict disease
extent on the basis of multivariate regression analysis and
reported a sensitivity of 91% and 53% and a specificity of
41% and 94% for the prediction of organ confinement and
advanced disease, respectively. Moreover, several neural
networks, which can define nonlinear patterns between
predictor variables more precisely than linear statistical
models, have been introduced to predict disease extent.
9,16
The preoperative PSA level, the biopsy GS, the percent
of positive cores, and the maximum tumor volume of the
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DISCUSSIONpositive cores were determined to be the significant pre-
dictors of down-staging in our study. When the cut-off
points of the PSA was < 10 ng/mL, the percent of the
positive cores was ≤ 30%, the maximum tumor volume of
the positive cores was ≤ 75%, and the biopsy GS was ≤ 7,
and all these were combined, the sensitivity, specificity,
and PPV were 0.25, 1.00, and 100%, respectively. The
PSA value has been known to generally be correlated with
the cancer volume, GS, ECE, and the occurrence of lymph
node metastases. For example, one study showed that a
PSA level > 10 ng/mL has a sensitivity, specificity, and
PPV of 61%, 88%, and 88% for the detection of ECE,
respectively.
17 Narayan, et al. established probability plots
that can predict the presence of ECE, seminal vesicle in-
volvement, and lymph node metastases using PSA level.
18
In addition, according to previous studies, the percent of
positive cores or the maximum tumor volume of the positive
cores in the needle biopsy may provide excellent informa-
tion for disease extent. In a study of 207 patients, the
extent of cancer in the needle biopsy, as defined by the
percent of positive cores and the maximum tumor volume
of the positive cores, is strongly predictive of pathological
organ-confined diseases and the tumor volume at radical
prostatectomy.
19 For example, patients with 1 tumor posi-
tive biopsy of 6 biopsies or the tumor volume of the posi-
tive biopsy less than 5% had an approximately 10% or less
risk of ECE. The number of positive cores is jointly predic-
tive of ECE in a model incorporating the PSA level, the
clinical stage, and the GS; therefore, a model to predict
organ-confined disease should incorporate the extent of the
tumor in the needle biopsy.
20 Finally, patients with a GS 8
or 9 at the time of the needle biopsy were almost 12 times
as likely to have ECE at prostatectomy compared with
those patients with a GS ≤ 6.
21 Similarly, our data showed
that a patient with a biopsy GS ≤ 7 was 4.7 times as likely
to be down-staged to ≤ pT2 (p = 0.03, 1.3 ≤ 95% CI ≤
196.7) and the sensitivity, specificity, and PPV were 0.66,
0.50, and 83%, respectively. But although the GS, the extent
of carcinoma in the biopsy specimen, and the presence of
perineural invasion are significant indicators of either the
tumor volume or the pathologic stage, a previous model
that used these biopsy findings still revealed an inadequate
ability to predict the tumor volume and stage at RP.
19 And
high GS prostate cancer patients confined to the prostate at
histopathologic examinations have an excellent oncologic
outcome after RP.
22 Thus, ancillary markers, including DNA
ploidy or MIB-I, have been suggested as a new factor that
can enhance the ability to predict clinically significant out-
comes.
23,24
All the patients diagnosed with prostate cancer at our
institution routinely underwent a prostate MRI and we con-
sidered MRI findings to determine the clinical TNM stag-
ing, especially ≤ cT3 stage and treatment options instead of
DRE. Despite the introduction of new imaging techniques
and the refinement of existing techniques, it remains diffi-
cult to stage accurately in the preoperative period between
organ confined and locally advanced diseases. Ohori, et al.
reported that the PPV and NPV for detecting ECE were
74% and 64%, respectively, for DRE, and in another study,
the PPV and NPV of MRI for identifying ECE ranged
from 66% to 82% and from 30% to 90%, respectively.
25,26
The wide variation in the reliability of DRE and MRI for
determining the presence of ECE may come from the oper-
ator-dependent examinations, which depend on the pers-
onal skill and the interpretation of the test results by the
investigator. Although standard clinical staging evaluation
does not considers MRI but DRE, clinical assessment by
DRE and the measurement of the PSA level is not accurate
in determining the local stage, with underestimations in as
many as 40-60% of cases.
27 The sensitivity of DRE alone
in diagnosing non organ-confined diseases is poor: 20-
40% of men with nonpalpable diseases and 50-75% of
men with palpable clinical stage T2 tumors have extrapros-
tatic diseases at surgery and over-staging occurs in 10-20%
of men with clinically non organ-confined diseases.
28 There-
fore, accurate staging with additional imaging methods is
an important issue for correct management of prostate
cancer patients. 
Among these imaging techniques, MRI is considered to
play an important role in local staging of prostate cancer
and the role of MRI of the prostate has been debated exten-
sively in previous studies. In fact, the low sensitivity of
MRI for the detection of local extension (20-70%) or
lymph node metastasis (0-15%) also limits their usefulness
in clinical staging and their use was eliminated in patients
with PSA levels of < 20 ng/mL, which have a less than 1%
probability of lymph node involvement. However, recently,
with the introduction of new MR sequences, new coils,
and other technical developments instead of initially MR
imaging using a conventional body coil with limited anato-
mical resolution, the diagnostic capability of MRI imaging
in preoperative staging of prostate cancer was reported as a
maximum combined sensitivity and specificity of 71% in a
meta-analysis of all published studies evaluating the per-
formance of MR imaging in the local staging of prostate
cancer.
29 In another prospective study to compare the accu-
racy in predicting pathological stage in patients intended
for RP between 3-Tesla (T) MRI and the Partin tables, 3T
MRI showed a high accuracy (85.2%) for the staging of
clinically localized prostate cancer, and it was significantly
more accurate in predicting the final pathological stage
than the Partin tables.
30 In the present study, 53 (79%) pati-
ents were down-staged as ≤ pT2 after RP and this high rate
could be explained partly by the fact that we included clini-
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ques of prostate MRI were refined for satisfactory diagno-
stic accuracy. In addition, we selectively preformed RP for
the cT3 patients who had a low PSA level and fair biopsy
findings, although the imaging work-up was suspicious for
ECE or SVI, and this also could have caused the high
down-staging rate. Although an MRI can be incorporated
in the clinical work up of prostate cancer, there are several
limitations associated with local staging of the prostate by
an MRI. For example, a hemorrhage due to a biopsy can
show areas of low signal intensity that are similar to pros-
tate cancer and so this causes discrepancies between the
MRI and histopathology results. Moreover, an MRI cannot
detect microscopic invasion and none of the currently ava-
ilable imaging modalities allow for the detection of micro-
scopic invasion.
8 The recent introduction of multi-slice
dynamic contrast enhanced MRI and 1H MR spectroscopy
to dynamic MRI has achieved significant improvement for
tumor visualization and the staging performance for deter-
mining the presence of tumor extension by reducing the
inter-observer variability.
31,32 Of the total 67 patients with
cT3 stage disease, the neurovascular bundle saving techni-
que was applied to 10 (15%) patients (unilateral: 2, bilateral:
8) in our study. The patient parameters for performing
“safe” nerve-sparing surgery are controversial and generally,
those who are young and have organ-confined diseases
were considered optimal candidates in terms of the rates of
achieving a cure and maintaining a proper erectile function.
7
Various clinical parameters have recently been investigat-
ed as potential selection criteria to define the cancer-specific
safety of nerve-sparing surgery. Graefen, et al. proposed
that only well-differentiated cancer in the preoperative
biopsy and a maximum of one positive core on the evaluat-
ed side could be safe and more applicable criteria for nerve-
sparing RP.
33 The preoperative biopsy criteria includes
moderate grade unilateral tumors of patients having at least
three biopsy cores on the non-cancerous side in one study.
34
However, there are no official guidelines whether or not to
perform a nerve-sparing RP because of multifocality and
heterogeneity of prostate cancer; our results could be care-
fully considered when the nerve-sparing technique was
performed in RP for cT3 patients.
This study involved a small study population of a single
institution within a long duration and preoperatively staged
prostate cancer based on MRI findings, which is not usually
used or considered in traditional clinical T staging. In addi-
tion, RP was performed in a proportion of patients with
cT3 prostate cancer, so the findings of this study could not
be generalized in all cT3. Finally, although our study classi-
fied those patients with ≤ pT2 disease and positive surgical
margins as a down-staged group because the surgical
margin involvement was not considered in the pathological
staging, their prostate cancer was not organ-confined and
so these pathology findings could affect the prognosis after
RP. However, models promising performance for one group
of patients do not guarantee utility in another group and
differences in race, age, and comorbidity and variations in
retrieval and interpretation of clinical data may interfere
with an algorithm’s predictive performance. A larger, ran-
domized, multi-center study may provide promising an-
swers for constructing highly accurate models or algori-
thms that attempt to predict the down-staging at RP, and
these models or algorithms would incorporate the biopsy
findings and the newly developed and refined staging
modalities. Also, these models can be proved as safe para-
meters for nerve preservation by analyzing the oncologic
outcomes when they are considered in further studies.
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